Overview

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

Status:
RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial\] is to evaluate mitoxantrone hydrochloride liposomes, subcutaneous injection of cytarabine and G-CSF combined with Venetoclax (CMG+Ven) in adult secondary acute myeloid leukemia and myelodysplastic syndrome with increased primordial cells type 2(MDS-IB2) or elderly acute myeloid leukemia\]. The main questions it aims to answer are: * Evaluation of the efficacy * Evaluation of the safety
Phase:
NA
Details
Lead Sponsor:
Ruijin Hospital
Collaborators:
Army Medical Center of PLA
Dalian Municipal Central Hospital
First Hospital of China Medical University
Huadong Hospital
Huashan Hospital
RenJi Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Jiading District Central Hospital
Shanghai Public Health Clinical Center
Shanghai Pudong Hospital
Shanghai Zhongshan Hospital
Sun Yat-sen University
Taizhou First People's Hospital
The Affiliated People's Hospital of Ningbo University
The Second Affiliated Hospital of Dalian Medical University
Wenzhou People's Hospital
Xuhui Central Hospital, Shanghai